TET2 and acute myeloid leukemia: With respect to TET2 mutations, a meta-analysis by Liu et al. in 2552 AML patients showed that it was associated as an adverse prognostic indicator only in CN-AML (OS: HR, 1.43, 95% CI: 1.16–1.75, p = 0.001) [32].